A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
OBJECTIVE
We hypothesized that administration of bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, in combination with high-dose interferon-alpha2b (IFN-α2b), an inhibitor of basic fibroblast growth factor, would have clinical activity in patients with metastatic ocular melanoma.


METHODS
Patients with metastatic ocular melanoma received bevacizumab (15 mg/kg intravenously every 2 weeks) plus IFN-α2b (5 MU/m subcutaneously 3 times weekly for 2 weeks followed by a dose of 10 MU/m subcutaneously thereafter). Patients exhibiting a clinical response or stabilization of disease were treated until disease progression.


RESULTS
In this pilot study, 5 patients were treated (3 men, 2 women) with a mean age of 63.8 years (range, 53-71 years). Overall, the regimen was well-tolerated. The following adverse events were noted: grade 3 dyspnea (2 patients), grade 3 and 4 fatigue (2), grade 3 muscle weakness (1), grade 3 anorexia (1), grade 1 and 2 proteinuria (2), and grade 3 diarrhea (1). All adverse events resolved with a treatment holiday or dose reduction. One patient had reduction in tumor burden of 23% by Response Evaluation Criteria in Solid Tumors criteria and 2 patients had stabilization of disease lasting 28 and 36 weeks, respectively. Two patients failed to respond and progressed after 6 and 7 weeks of therapy.


CONCLUSIONS
Bevacizumab and IFN-α2b were well tolerated in this patient population, and clinical activity was observed. Further study of high-dose IFN-α2b in combination with bevacizumab in this setting is warranted.
Guenterberg
Kristan D
KD
Division of Surgical Oncology, The Ohio State University, Columbus, Ohio 43210, USA.
Grignol
Valerie P
VP
Relekar
Kiran V
KV
Varker
Kimberly A
KA
Chen
Helen X
HX
Kendra
Kari L
KL
Olencki
Thomas E
TE
Carson
William E
WE
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D011994:Recombinant Proteins; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068258:Bevacizumab
Eur J Cancer. 2003 May;39(8):1115-20
12736111
Ophthalmic Res. 2007;39(1):40-4
17164576
Br J Ophthalmol. 2002 Apr;86(4):448-52
11914216
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
J Exp Clin Cancer Res. 1997 Jun;16(2):201-8
9261748
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2471-80
10509639
Br J Ophthalmol. 2002 Apr;86(4):440-7
11914215
Semin Ophthalmol. 2006 Jul-Sep;21(3):151-60
16912013
Melanoma Res. 1999 Oct;9(5):445-50
10596910
Drugs. 2005;65(6):733-43
15819587
Oncogene. 1999 May 6;18(18):2798-810
10362250
Curr Eye Res. 2006 Sep;31(9):775-85
16966150
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
Ophthalmol Clin North Am. 2005 Mar;18(1):75-84, viii
15763193
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Invest New Drugs. 2008 Dec;26(6):561-5
18551246
Surgery. 1979 Jul;86(1):36-40
572101
Arch Dermatol. 2008 Apr;144(4):525-7
18427047
J Clin Oncol. 2012 Jan 1;30(1):34-41
22124101
Arch Ophthalmol. 1996 Jan;114(1):107-8
8540843
J Cell Biol. 1995 May;129(4):895-8
7538139
Cancer. 2002 Dec 1;95(11):2366-72
12436444
Cancer Res. 1996 Jul 1;56(13):2900-3
8674036
Cancer Res. 2001 Oct 1;61(19):7282-90
11585767
Microsc Res Tech. 2003 Feb 1;60(2):208-24
12539175
Curr Eye Res. 2006 Jun;31(6):557-62
16769615
Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2002-7
8700875
N Engl J Med. 2003 Jul 31;349(5):427-34
12890841
J Interferon Cytokine Res. 2008 Sep;28(9):553-61
18771339
Cancer Treat Rev. 2008 May;34(3):247-58
18226859
N Engl J Med. 1992 May 28;326(22):1456-63
1489383
J Surg Oncol. 2005 Sep 1;91(3):173-80
16118771
Cancer. 1998 Oct 15;83(8):1664-78
9781962
Exp Eye Res. 1996 Nov;63(5):511-8
8994354
Nat Med. 2003 Jun;9(6):669-76
12778165
Br J Ophthalmol. 2000 Jul;84(7):750-6
10873988
N Engl J Med. 2008 May 8;358(19):2039-49
18463380
J Clin Oncol. 2005 Feb 1;23(4):792-9
15681523
Oncology. 2005;69 Suppl 3:25-33
16301833
Cancer Res. 1998 Feb 15;58(4):808-14
9485039